Keywords: ریتوکسیماب; Organ transplantation; Rituximab; Lymphocyte crossmatch assay;
مقالات ISI ریتوکسیماب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ریتوکسیماب; Caplan syndrome; Rheumatoid arthritis; Silicosis; Chest CT scan; Rituximab;
Keywords: ریتوکسیماب; Orbital inflammatory disease; Rituximab; Eyelid reconstruction; Granulomatosis with polyangiitis;
Keywords: ریتوکسیماب; ADEM; ON; MOG; Rituximab;
Keywords: ریتوکسیماب; Type 1 hyperlipidemia; Hyperchylomicronemia; Autoimmune hyperlipidemia; Rituximab; Anti-LPL autoantibody;
Keywords: ریتوکسیماب; Azathioprine; Mycophenolate mofetil; Rituximab; Neuromyelitis optica spectrum disorder (NMOSD); Treatment;
Keywords: ریتوکسیماب; Mantle cell lymphoma; Geriatric assessment; Chemotherapy; Ibrutinib; Rituximab; Bendamustine; Lymphoma;
Keywords: ریتوکسیماب; Giant cell arteritis; Takayasu arteritis; Anti-TNF-α agents; Tocilizumab; Ustekinumab; Rituximab; Abatacept;
Keywords: ریتوکسیماب; AID; AutoImune Disease; CMV; Cytomegalovirus; CTCAE; Common Terminological Criteria of Adverse Events; ICU; Intensive Care Unit; IE; Infectious Event; MHD; Monoclonal Hematological Disorder; PML; Progressive Multifocal Leukoencephalopathy; SIE; Severe Inf
Keywords: ریتوکسیماب; Follicular lymphoma; Elderly patients; Rituximab; Immunochemotherapy; Maintenance; Survival;
Keywords: ریتوکسیماب; Neuromyelitis optica; Rituximab; Guidelines; Recommendations; Treatment;
Keywords: ریتوکسیماب; Urticaria; Biomarkers; CRP; IL-6; MPV; D-dimer; F1+2; Biologics; Omalizumab; ASCENT-I; ASCENT-II; GLACIAL; IL-1 antagonists; TNF-α inhibitors; Intravenous immunoglobulin; Rituximab; Ligelizumab; Quilizumab; ASST; Autologous serum skin test; ATA; Antithyr
Keywords: ریتوکسیماب; rituximab; idiopathic membranous nephropathy; nephrotic syndrome; meta analysis;
Keywords: ریتوکسیماب; Catastrophic antiphospholipid syndrome; Therapeutics; Anticoagulation; Corticoids; Plasma exchange; Intravenous immunoglobulins; Rituximab; Eculizumab; Sirolimus;
Keywords: ریتوکسیماب; AZA; azathioprine; ADA; adalimumab; CYA; cyclosporine A; CYX; cyclophosphamide; ETN; etanercept; FK; tacrolimus; IFX; infliximab; IS; immunosuppressant; LFM; leflunomide; MMF; mycophenolate mofetil; MTX; methotrexate; RTX; rituximab; TAK; Takayasu's Arter
Keywords: ریتوکسیماب; Autoimmune retinopathy; Cancer-associated retinopathy; Melanoma-associated retinopathy; Retinal degeneration; Antiretinal antibodies; Rituximab; Paraneoplastic;
Keywords: ریتوکسیماب; Rapid drug desensitization; One-solution protocol; Drug allergy; Oxaliplatin; Carboplatin; Paclitaxel; Docetaxel; Cetuximab; Rituximab; CTCAE v.3; Common Terminology Criteria for Adverse Events, Version 3.0; IDT; Intradermal test; SPT; Skin prick test; ST
Keywords: ریتوکسیماب; Kaposi sarcoma herpesvirus; Human herpesvirus-8; Multicentric Castleman disease; Human interleukin-6; Viral interleukin 6; Rituximab; Liposomal doxorubicin;
Keywords: ریتوکسیماب; Multiple sclerosis; Ulcerative colitis; Autoimmune hepatitis; Rituximab;
Keywords: ریتوکسیماب; Primary hepatic; Marginal zone B-cell lymphoma; Mucosa-associated lymphoid tissue (MALT lymphoma); Waldenstorms macroglobulinemia; Rituximab;
Keywords: ریتوکسیماب; Castleman disease; Treatment; Rituximab; Corticosteroids; Chemotherapy; Tocilizumab; Siltuximab;
Keywords: ریتوکسیماب; Systemic sclerosis; Rituximab; Interstitial lung disease;
Keywords: ریتوکسیماب; Rheumatoid arthritis; Rituximab; Prediction; Type I interferon;
Keywords: ریتوکسیماب; Cladribine; HCL treatment; Rituximab; Treatment efficacy; Vemurafenib;
Keywords: ریتوکسیماب; Autoimmune pancreatitis; Lymphoplasmacytic sclerosing pancreatitis; Idiopathic duct centric pancreatitis; IgG-4; Corticosteroids; Immunomodulator; Azathioprine; Rituximab;
Keywords: ریتوکسیماب; Follicular lymphoma; Early therapy failure; Autologous transplantation; Early transplant; Rituximab; Chemoimmunotherapy;
Keywords: ریتوکسیماب; Biologics; Inflammatory Bowel Disease; Crohn's Disease; Ulcerative Colitis; AEs; adverse events; CD; Crohn's disease; DMARDs; disease-modifying antirheumatic drug; IBD; inflammatory bowel disease; MTX; methotrexate; RA; rheumatoid arthritis; RTX; rit
Keywords: ریتوکسیماب; Protein purification; Temperature-responsive polymer; Poly(N-isopropylacrylamide); Protein activity; Monoclonal antibody; Rituximab;
Keywords: ریتوکسیماب; Costs; Long-term outcome; Monoclonal antibody; Myasthenia gravis; Pregnancy; Rituximab; Safety; Treatment;
Keywords: ریتوکسیماب; Autologous stem cell transplant; Cytarabine; High dose; Mantle cell lymphoma; Rituximab;
Keywords: ریتوکسیماب; Myasthenia gravis; Immunomodulatory therapy; Rituximab; Tocilizumab;
Keywords: ریتوکسیماب; Hashimoto encephalopathy; corticosteroid treatment; anti-B-cell therapy; rituximab; hypogammaglobulinemia;
Keywords: ریتوکسیماب; Eltrombopag; rituximab; romiplostim; thrombocytopenia; thrombopoietin;
Keywords: ریتوکسیماب; Thrombotic thrombocytopenic purpura; Refractory disease; ADAMTS13; Rituximab; Immunotherapy;
Keywords: ریتوکسیماب; Follicular lymphoma; Maintenance therapy; Rituximab;
Keywords: ریتوکسیماب; Rituximab; Monoclonal antibody; Infusion reaction; Desensitization;
Keywords: ریتوکسیماب; Resistant myasthenia gravis; Rituximab; Retrospective cohort; Progressive multifocal leukoencephalopathy;
Keywords: ریتوکسیماب; Lymphoma, non-Hodgkin; Splenic marginal zone lymphoma; Splenic lymphoma; Indolent lymphoma; Rituximab;
Keywords: ریتوکسیماب; autoantibodies; autoimmune bullous diseases; immunology; pemphigus; pemphigus foliaceus; pemphigus vulgaris; prediction; relapse; rituximab; Dsg1; desmoglein 1 antibody; Dsg3; desmoglein 3 antibody; EKM; extended Kaplan-Meier; PDAI; Pemphigus Disease Area
Keywords: ریتوکسیماب; systemic lupus erythematosus; rituximab; pediatric; child; treatment outcome; systematic review; LUNAR; Lupus Nephritis Assessment with Rituximab; pSLE; Pediatric systemic lupus erythematosus; RTX; Rituximab; SLE; Systemic lupus erythematosus;
Keywords: ریتوکسیماب; pFLCs; polyclonal free light chains; IMWG; International Myeloma Working Group; SMM; smoldering multiple myeloma; mFLCs; monoclonal FLCs; CSF; cerebrum-spinal fluid; RA; rheumatoid arthritis; SLE; systemic lupus erythematosus; Anti-Ro/SSA; Anti-Sjögren's
Keywords: ریتوکسیماب; Paraneoplastic pemphigus; Rituximab; Antibody production; Lymphoproliferative origin; Prognosis; Pemphigus; Pénfigo paraneoplásico; Rituximab; Producción de anticuerpos; Origen linfoproliferativo; Pronóstico; Pénfigo;
Keywords: ریتوکسیماب; Bortezomib; BTK; Clinical trial; Copanlisib; Ibritumomab tiuxetan; Ibrutinib; Idelalisib; Lenalidomide; Marginal zone lymphoma; Obinutuzumab; PI3K; Radioimmunotherapy; Rituximab; TGR-1202; Ublituximab; Venetoclax;
Keywords: ریتوکسیماب; Pemphigus; Autoimmune disease; Treatment; Rituximab; Intravenous immunoglobulin; Personalized medicine;
Keywords: ریتوکسیماب; Follicular lymphoma; Maintenance; Rituximab; Meta-analysis;
Keywords: ریتوکسیماب; PCNSL; Radiotherapy; Cerebrospinal fluid; Methotrexate; Cytarabine; Thiotepa; Rituximab;
Keywords: ریتوکسیماب; Therapeutic monoclonal antibody; Multivalent antibody; Rituximab; Lipid nanoparticles; Lymphoma;
Keywords: ریتوکسیماب; Progressive multifocal leukoencephalopathy; Biologic therapy; Synthetic immunosuppressive therapy; Autoimmune rheumatic diseases; Systemic lupus erythematosus; Rituximab;
Keywords: ریتوکسیماب; Biologic agents; Monoclonal antibodies; Infusion reaction; Delayed reaction; Drug desensitization; Omalizumab; Rituximab;
Keywords: ریتوکسیماب; Chronic lymphocytic leukaemia; guideline; lymphoma; rituximab; systematic review;